Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rare Variants in Calcium Homeostasis Modulator 1 (CALHM1) Found in Early Onset Alzheimer's Disease Patients Alter Calcium Homeostasis

  • Rubio-Moscardo, Fanny
  • Setó-Salvia, Núria|||0000-0002-3753-0027
  • Pera, Marta|||0000-0003-4317-6623
  • Bosch-Morató, Mònica
  • Plata, Cristina
  • Belbin, Olivia|||0000-0002-6109-6371
  • Gené, Gemma G.
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Ingelsson, Martin|||0000-0001-5466-8370
  • Helisalmi, Seppo
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Hiltunen, Mikko|||0000-0003-3566-4096
  • Giedraitis, Vilmantas|||0000-0003-3423-2021
  • Lannfelt, Lars
  • Frank García, Ana
  • Bullido, MªJesús
  • Combarros, Onofre
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Boada, Mercè|||0000-0003-2617-3009
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Pastor, Pau|||0000-0002-7493-8777
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Baquero, Miquel|||0000-0002-6861-1831
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fuentes-Prior, Pablo|||0000-0002-6618-3204
  • Fortea, Juan|||0000-0002-1340-638X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Muñoz, Francisco J.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Valverde, Miguel A.
  • Clarimón, Jordi|||0000-0002-6824-6942
Calcium signaling in the brain is fundamental to the learning and memory process and there is evidence to suggest that its dysfunction is involved in the pathological pathways underlying Alzheimer's disease (AD). Recently, the calcium hypothesis of AD has received support with the identification of the non-selective Ca-permeable channel CALHM1. A genetic polymorphism (p. P86L) in CALHM1 reduces plasma membrane Ca permeability and is associated with an earlier age-at-onset of AD. To investigate the role of CALHM1 variants in early-onset AD (EOAD), we sequenced all CALHM1 coding regions in three independent series comprising 284 EOAD patients and 326 controls. Two missense mutations in patients (p.G330D and p.R154H) and one (p.A213T) in a control individual were identified. Calcium imaging analyses revealed that while the mutation found in a control (p.A213T) behaved as wild-type CALHM1 (CALHM1-WT), a complete abolishment of the Ca influx was associated with the mutations found in EOAD patients (p.G330D and p.R154H). Notably, the previously reported p. P86L mutation was associated with an intermediate Ca influx between the CALHM1-WT and the p.G330D and p.R154H mutations. Since neither expression of wild-type nor mutant CALHM1 affected amyloid ß-peptide (Aß) production or Aß-mediated cellular toxicity, we conclude that rare genetic variants in CALHM1 lead to Ca dysregulation and may contribute to the risk of EOAD through a mechanism independent from the classical Aß cascade. © 2013 Rubio-Moscardo et al.
Repisalud
Publicación Artículo científico (JournalArticle)

Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

  • Marrugal, Ángela
  • Ferrer, Irene
  • Pastor, Maria Dolores
  • Ojeda, Laura
  • Quintanal-Villalonga, Alvaro
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Heat shock protein 90 (HSP90) is an important chaperone in lung adenocarcinoma, with relevant protein drivers such as EGFR (epidermal growth factor receptor) and EML4-ALK (echinoderm microtubule-associated protein-like protein4 fused to anaplastic lymphoma kinase) depending on it for their correct function, therefore HSP90 inhibitors show promise as potential treatments for lung adenocarcinoma. To study responses to its inhibition, HSP90 was pharmacologically interrupted by geldanamycin and resorcinol derivatives or with combined inhibition of HSP90 plus HSP70 in lung adenocarcinoma cell lines. Two-dimensional electrophoresis was performed to identify proteomic profiles associated with inhibition which will help to understand the biological basis for the responses. HSP90 inhibition resulted in altered protein profiles that differed according the treatment condition studied. Results revealed 254 differentially expressed proteins after treatments, among which, eukaryotic translation initiation factor3 subunit I (eIF3i) and citrate synthase demonstrated their potential role as response biomarkers. The differentially expressed proteins also enabled signalling pathways involved in responses to be identified; these included apoptosis, serine-glycine biosynthesis and tricarboxylic acid cycle. The proteomic profiles identified here contribute to an improved understanding of HSP90 inhibition and open possibilities for the detection of potential response biomarkers which will be essential to maximize treatment efficacy in lung adenocarcinoma.
Repisalud
Publicación Artículo científico (JournalArticle)

Histology-dependent prognostic role of pERK and p53 protein levels in early-stage non-small cell lung cancer

  • Quintanal-Villalonga, Alvaro
  • Mediano, Mariló
  • Ferrer, Irene
  • Meléndez, Ricardo
  • Carranza-Carranza, Andrés
  • Suárez, Rocío
  • Carnero, Amancio
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
Lung tumors represent a major health problem. In early stage NSCLC tumors, surgical resection is the preferred treatment, but 30-55% of patients will relapse within 5 years after surgery. Thus, the identification of prognostic biomarkers in early stage NSCLC patients, especially those which are therapeutically addressable, is crucial to enhance survival of these patients. We determined the immunohistochemistry expression of key proteins involved in tumorigenesis and oncogenic signaling, p53, EGFR, pAKT and pERK, and correlated their expression level to clinicopathological characteristics and patient outcome. We found EGFR expression is higher in the squamous cell carcinomas than in adenocarcinomas (p=0.043), and that nuclear p53 staining correlated with lower differentiated squamous tumors (p=0.034). Regarding the prognostic potential of the expression of these proteins, high pERK levels proved to be an independent prognostic factor for overall (p<0.001) and progression-free survival (p<0.001) in adenocarcinoma patients, but not in those from the squamous histology, and high p53 nuclear levels were identified as independent prognostic factor for progression-free survival (p=0.031) only in squamous cell carcinoma patients. We propose a role as early prognostic biomarkers for pERK protein levels in adenocarcinoma, and for nuclear p53 levels in squamous cell lung carcinoma. The determination of these potential biomarkers in the adequate histologic context may predict the outcome of early stage NSCLC patients, and may offer a therapeutic opportunity to enhance survival of these patients.
Repisalud
Publicación Artículo científico (JournalArticle)

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

  • Ferrer, Irene
  • Quintanal-Villalonga, Alvaro
  • Molina-Pinelo, Sonia
  • Garcia-Heredia, Jose Manuel
  • Perez, Marco
  • Suárez, Rocío
  • Ponce-Aix, Santiago
  • Paz Ares , Luis Gonzaga
  • Carnero, Amancio
BACKGROUND: The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient survival. MAP17 (PDZK1IP1) is a small membrane-bound protein whose upregulation is reported as a common feature in tumours from diverse histological origins. Furthermore, MAP17 is correlated with tumour progression. METHODS: We assessed the expression of MAP17 in preclinical models, including cell lines and patient-derived xenografts (PDXs), assessing its correlation with sensitivity to different standard-of-care drugs in lung adenocarcinoma, as well as novel drugs. At the clinical level, we subsequently correlated MAP17 expression in human tumours with patient response to these therapies. RESULTS: We show that MAP17 expression is induced during lung tumourigenesis, particularly in lung adenocarcinomas, and provide in vitro and in vivo evidence that MAP17 levels predict sensitivity to therapies currently under clinical use in adenocarcinoma tumours, including cisplatin, carboplatin and EGFR inhibitors. In addition, we show that MAP17 expression predicts proteasome inhibitor efficacy in this context and that bortezomib, an FDA-approved drug, may be a novel therapeutic approach for MAP17-overexpressing lung adenocarcinomas. CONCLUSIONS: Our results indicate a potential prognostic role for MAP17 in lung tumours, with particular relevance in lung adenocarcinomas, and highlight the predictive pot0065ntial of this membrane-associated protein for platinum-based therapy and EGFR inhibitor efficacy. Furthermore, we propose bortezomib treatment as a novel and efficacious therapy for lung adenocarcinomas exhibiting high MAP17 expression.
Repisalud
Publicación Artículo científico (JournalArticle)

The FGFR4-388arg Variant Promotes Lung Cancer Progression by N-Cadherin Induction

  • Quintanal-Villalonga, Alvaro
  • Ojeda-Marquez, Laura
  • Marrugal, Ángela
  • Yagüe, Patricia
  • Ponce-Aix, Santiago
  • Salinas, Ana
  • Carnero, Amancio
  • Ferrer, Irene
  • Molina-Pinelo, Sonia
  • Paz Ares , Luis Gonzaga
The FGFR4-388Arg variant has been related to poor prognosis in several types of cancer, including lung cancer. The mechanism underlying this association has not been addressed in detail in patients with this pathology. Here, we report that this FGFR4 variant induces MAPK and STAT3 activation and causes pro-oncogenic effects in NSCLC in vitro and in vivo. This variant induces the expression of EMT-related genes, such as N-cadherin, vimentin, Snail1 and Twist1. Indeed, the induction of N-cadherin protein expression by this variant is essential for its pro-tumorigenic role. The presence of the FGFR4-388Arg variant correlates with higher N-cadherin expression levels in clinical NSCLC samples and with poorer outcome in patients with FGFR expression. These results support the prognostic role of this FGFR variant in lung cancer and show that these effects may be mediated by the induction of N-cadherin expression and an EMT phenotype.
Repisalud
Publicación Artículo científico (JournalArticle)

Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement

  • Quintanal-Villalonga, Alvaro
  • Carranza-Carranza, Andrés
  • Meléndez, Ricardo
  • Ferrer, Irene
  • Molina-Pinelo, Sonia
  • Paz Ares, Luis Gonzaga
BACKGROUND: The identification of prognostic biomarkers for lung squamous-cell carcinoma (SCC) pathology is crucial because of its poor prognosis. A variant of the FGFR4 (fibroblast growth factor receptor 4) gene, FGFR4-388Arg, has been associated with prognosis and is linked to oncogenesis in vitro in several types of cancer. We analyzed the association of this variant with prognosis and downstream signaling alteration in lung SCC patients. METHODS: The presence of the FGFR4-388Arg variant was determined in 114 formalin-fixed, paraffin-embedded lung SCC tissue samples by DNA genotyping and was correlated with clinicopathologic data. The activation of the protein kinase B (AKT) and mitogen-activated protein kinase (MAPK) pathways was determined by immunohistochemistry, and its association with the presence of FGFR4-388Arg was analyzed. RESULTS: We found that tumor differentiation status and adjuvant chemotherapy administration could be independent prognostic factors for overall survival (OS) in lymph node-affected patients, as expected. The progression-free survival and OS of patients with lymph node involvement (n = 41) and the FGFR4-388Arg genotype were significantly lower than those of patients lacking this variant (P = .035 and P = .042, respectively). Importantly, multivariate analysis supported the independent prognostic role of the FGFR4-388Arg genotype in OS (P = .025). Regarding downstream signaling, the FGFR4-388Arg genotype was not correlated with altered AKT signaling but was associated with increased MAPK activation in the SCC tumor samples (P = .017). CONCLUSION: The FGFR4-388Arg variant may represent a promising prognostic biomarker in SCC patients with lymph node involvement. For these patients, FGFR4 may be a potential therapeutic target.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Identification of the presence of ischaemic stroke lesions by means of texture analysis on brain magnetic resonance images

  • Ortiz-Ramón, Rafael
  • Valdés Hernández, Maria del C.
  • González-Castro, Victor
  • Makin, Stephen
  • Armitage, Paul A.
  • Aribisala, Benjamin S.
  • Bastin, Mark E.
  • Deary, Ian J.
  • Wardlaw, Joanna M.
  • Moratal, David|||0000-0002-2825-3646
[EN] Background: The differential quantification of brain atrophy, white matter hyperintensities (WMH) and stroke lesions is important in studies of stroke and dementia. However, the presence of stroke lesions is usually overlooked by automatic neuroimage processing methods and the-state-of-the-art deep learning schemes, which lack sufficient annotated data. We explore the use of radiomics in identifying whether a brain magnetic resonance imaging (MRI) scan belongs to an individual that had a stroke or not. Materials and methods: We used 1800 3D sets of MRI data from three prospective studies: one of stroke mechanisms and two of cognitive ageing, evaluated 114 textural features in WMH, cerebrospinal fluid, deep grey and normal-appearing white matter, and attempted to classify the scans using a random forest and support vector machine classifiers with and without feature selection. We evaluated the discriminatory power of each feature independently in each population and corrected the result against Type 1 errors. We also evaluated the influence of clinical parameters in the classification results. Results: Subtypes of ischaemic strokes (i.e. lacunar vs. cortical) cannot be discerned using radiomics, but the presence of a stroke-type lesion can be ascertained with accuracies ranging from 0.7 < AUC < 0.83. Feature selection, tissue type, stroke subtype and MRI sequence did not seem to determine the classification results. From all clinical variables evaluated, age correlated with the proportion of images classified correctly using either different or the same descriptors (Pearson r = 0.31 and 0.39 respectively, p < 0.001). Conclusions: Texture features in conventionally automatically segmented tissues may help in the identification of the presence of previous stroke lesions on an MRI scan, and should be taken into account in transfer learning strategies of the-state-of-the-art deep learning schemes., This work was funded by the Row Fogo Charitable Trust (MVH, VGC) grant no. BRO-D.FID3668413, and the Wellcome Trust (patient recruitment, scanning, primary study Ref No. 088134/Z/09). The study was conducted independently of the funders who do not hold the data and did not participate in the study design or analyses. The Lothian Birth Cohort 1936 is funded by Age UK (Disconnected Mind grant) and the Medical Research Council (MRC; MR/M01311/1, G1001245, 82800), and the latter supported BSA. IJD was supported by the Centre for Cognitive Ageing and Cognitive Epidemiology, which is funded by the MRC and the Biotechnology and Biological Sciences Research Council (MR/K026992/1). David Moratal acknowledges financial support from the Spanish Ministerio de Economia y Competitividad (MINECO) and FEDER funds under Grant BFU2015-64380-C2-2-R, and from the Conselleria d'Educacio, Investigacio, Cultura i Esport, Generalitat Valenciana (grants AEST/2017/013 and AEST/2018/021). Rafael Ortiz-Ramon was supported by grant ACIF/2015/078 and grant BEFPI/2017/004 from the Conselleria d'Educacio, Investigacio, Cultura i Esport of the Valencian Community (Spain). We thank participants in the studies that provided data for this study, the radiographers and staff at the Brain Research Imaging Centre Edinburgh (http://www.bric.ed.ac.uk/), a SINAPSE (Scottish Imaging Network A Platform for Scientific Excellence, www. sinapse.ac.uk/) collaboration centre. We especially thank the following members of the research teams, who contributed to the recruitment, data collection or image processing in the primary studies, but did not participate in the analysis or writing of this report: Dr. Susana Munoz Maniega, Dr. Natalie Royle, Mrs. Eleni Sakka, Miss. Catherine Murray, Miss Kirsten Shuler.
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

MiRNA differences related to treatment-resistant schizophrenia

  • Pérez Rodríguez, Daniel
  • Penedo, Maria Aránzazu
  • Rivera Baltanás, Tania
  • Peña Centeno, Tonatiuh
  • Burkhardt, Susanne
  • Fischer, Andre
  • Prieto González, José M.
  • Olivares, José Manuel
  • López Fernández, Hugo
  • Agis Balboa, Roberto Carlos
Schizophrenia (SZ) is a serious mental disorder that is typically treated with antipsychotic medication. Treatment-resistant schizophrenia (TRS) is the condition where symptoms remain after pharmacological intervention, resulting in long-lasting functional and social impairments. As the identification and treatment of a TRS patient requires previous failed treatments, early mechanisms of detection are needed in order to quicken the access to effective therapy, as well as improve treatment adherence. In this study, we aim to find a microRNA (miRNA) signature for TRS, as well as to shed some light on the molecular pathways potentially involved in this severe condition. To do this, we compared the blood miRNAs of schizophrenia patients that respond to medication and TRS patients, thus obtaining a 16-miRNA TRS profile. Then, we assessed the ability of this signature to separate responders and TRS patients using hierarchical clustering, observing that most of them are grouped correctly (~70% accuracy). We also conducted a network, pathway analysis, and bibliography search to spot molecular pathways potentially altered in TRS. We found that the response to stress seems to be a key factor in TRS and that proteins p53, SIRT1, MDM2, and TRIM28 could be the potential mediators of such responses. Finally, we suggest a molecular pathway potentially regulated by the miRNAs of the TRS profile., Instituto de Salud Carlos III | Ref. PI18/01311, Xunta de Galicia | Ref. ED431C 2022/03-GRC
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

Application of miRNA-seq in neuropsychiatry: A methodological perspective

  • Pérez Rodríguez, Daniel
  • López Fernández, Hugo
  • Agís Balboa, Roberto C.
MiRNAs are emerging as key molecules to study neuropsychiatric diseases. However, despite the large number of methodologies and software for miRNA-seq analyses, there is little supporting literature for researchers in this area. This review focuses on evaluating how miRNA-seq has been used to study neuropsychiatric diseases to date, analyzing both the main findings discovered and the bioinformatics workflows and tools used from a methodological perspective. The objective of this review is two-fold: first, to evaluate current miRNA-seq procedures used in neuropsychiatry; and second, to offer comprehensive information that can serve as a guide to new researchers in bioinformatics. After conducting a systematic search (from 2016 to June 30, 2020) of articles using miRNA-seq in neuropsychiatry, we have seen that it has already been used for different types of studies in three main categories: diagnosis, prognosis, and mechanism. We carefully analyzed the bioinformatics workflows of each study, observing a high degree of variability with respect to the tools and methods used and several methodological complexities that are identified and discussed in this review, Instituto de Salud Carlos III | Ref. PI18/01311, Ministerio de Economía y Competitividad | Ref. RYC2014-15246, Xunta de Galicia | Ref. ED431C2018/55-GRC
Investigo. Repositorio Institucional de la Universidade de Vigo
Publicación Artículo científico (JournalArticle)

MyBrain-Seq: a pipeline for MiRNA-seq data analysis in neuropsychiatric disorders

  • Pérez Rodríguez, Daniel
  • Agis Balboa, Roberto Carlos
  • López Fernández, Hugo
High-throughput sequencing of small RNA molecules such as microRNAs (miRNAs) has become a widely used approach for studying gene expression and regulation. However, analyzing miRNA-Seq data can be challenging because it requires multiple steps, from quality control and preprocessing to differential expression and pathway-enrichment analyses, with many tools and databases available for each step. Furthermore, reproducibility of the analysis pipeline is crucial to ensure that the results are accurate and reliable. Here, we present myBrain-Seq, a comprehensive and reproducible pipeline for analyzing miRNA-Seq data that incorporates miRNA-specific solutions at each step of the analysis. The pipeline was designed to be flexible and user-friendly, allowing researchers with different levels of expertise to perform the analysis in a standardized and reproducible manner, using the most common and widely used tools for each step. In this work, we describe the implementation of myBrain-Seq and demonstrate its capacity to consistently and reproducibly identify differentially expressed miRNAs and enriched pathways by applying it to a real case study in which we compared schizophrenia patients who responded to medication with treatment-resistant schizophrenia patients to obtain a 16-miRNA treatment-resistant schizophrenia profile., Instituto de Salud Carlos III | Ref. PI18/01311, Xunta de Galicia | Ref. ED431C2018/55-GRC, Xunta de Galicia | Ref. ED431C 2022/03-GRC, Xunta de Galicia | Ref. TR349V
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Regulation of cortico-thalamic JNK1/2 and ERK1/2 MAPKs and apoptosis-related signaling pathways in PDYN gene-deficient mice following acute and chronic mild stress

  • Yáñez-Gómez, Fernando
  • Ramos-Miguel, Alfredo
  • García-Sevilla, Jesús Andrés
  • Manzanares, Jorge
  • Femenía, Teresa
This article belongs to the Special Issue Involvement of the MAPK Pathway in Cancer and Immunology., The crosstalk between the opioidergic system and mitogen-activated protein kinases (MAPKs) has a critical role in mediating stress-induced behaviors related to the pathophysiology of anxiety. The present study evaluated the basal status and stress-induced alterations of cortico-thalamic MAPKs and other cell fate-related signaling pathways potentially underlying the anxiogenic endophenotype of PDYN gene-deficient mice. Compared to littermates, PDYN knockout (KO) mice had lower cortical and or thalamic amounts of the phospho-activated MAPKs c-Jun N-terminal kinase (JNK1/2) and extracellular signal-regulated kinase (ERK1/2). Similarly, PDYN-KO animals displayed reduced cortico-thalamic densities of total and phosphorylated (at Ser191) species of the cell fate regulator Fas-associated protein with death domain (FADD) without alterations in the Fas receptor. Exposure to acute restraint and chronic mild stress stimuli induced the robust stimulation of JNK1/2 and ERK1/2 MAPKs, FADD, and Akt-mTOR pathways, without apparent increases in apoptotic rates. Interestingly, PDYN deficiency prevented stress-induced JNK1/2 and FADD but not ERK1/2 or Akt-mTOR hyperactivations. These findings suggest that cortico-thalamic MAPK- and FADD-dependent neuroplasticity might be altered in PDYN-KO mice. In addition, the results also indicate that the PDYN gene (and hence dynorphin release) may be required to stimulate JNK1/2 and FADD (but not ERK1/2 or Akt/mTOR) pathways under environmental stress conditions., This joint research was funded by Red Temática de Investigación Cooperativa en Salud–Red de Trastornos Adictivos (RETICS–RTA, Instituto de Salud Carlos III [ISCIII], MCIU/AEI/FEDER), Grupos RD06/0001/0004 (J.M.) and RD06/0001/0003 (J.A.G.-S.). J.M. also received financial support from Proyectos de Investigación en Salud—ISCIII (grant RD. PI18/00576), Red de Investigación en Atención Primaria de Adicciones (grant RD21/0009/0008), and Delegación del Gobierno para el Plan Nacional Sobre Drogas (PNSD, grant 2019I012) from the Spanish Ministry of Health (MSC). This study was also supported by MCIU/AEI/FEDER (grants RTI2018-094414-A-I00 to A.R.-M., PID2019-109323RA-I00 to T.F., and SAF2008-01311 to J.A.G.-S.), and MSC/FEDER (FIS 05/0429 to J.M). A.R.-M. (grant RYC-2016-19282) and T.F. (grant RYC-2017-22666) are ‘Ramón y Cajal’ Researchers., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Interleukin-11 promotes lung adenocarcinoma tumourigenesis and immune evasion

  • Cirauqui, Cristina
  • Ojeda, Laura
  • Otano, Itziar
  • Pazos, Irene
  • Santos, Alba
  • Garrido-Martin, Eva M.
  • Yagüe, Patricia
  • Ramos-Paradas, Javier
  • Molina-Pinelo, Sonia
  • Roncador, Giovanna
  • Solórzano, José Luis
  • Muñoz Jiménez, María Teresa
  • Cozar, Patricia
  • Plaza, Patricia
  • Suárez, Rocío
  • Jiménez, Marta
  • Moreno, Roberto
  • Rosado, Arantxa
  • Gámez, Pablo
  • García-Luján, Ricardo
  • Zugazagoitia, Jon
  • Sweet-Cordero, Alejandro
  • Barbacid, Mariano
  • Carnero, Amancio
  • Ferrer, Irene
  • Paz-Ares, Luis
Cristina Cirauqui, Laura Ojeda, Irene Ferrer and Luis Paz-Ares contributed equally to this work., [Rationale] Interleukin-11 (IL-11) has emerged as a significant player in tumourigenesis, with implications across various cancer types. However, its specific role in driving tumour progression in lung adenocarcinoma (LUAD) remains elusive. IL-11's multifaceted impact on both tumour cells and the tumour microenvironment underscores its potential as a therapeutic target in LUAD. This study aims to unravel the involvement of IL-11 in LUAD progression and its influence on the tumour microenvironment., [Methods] Here, we used transcriptomic and digital spatial profiling analyses together with clinic data from two retrospective LUAD patient cohorts. LUAD cell lines genetically engineered to overexpress or to silence IL-11 or its receptor (IL-11RA) were used for in vitro functional analysis and for in vivo experiments. Additionally, we used three different in vivo models: patient-derived xenografts (PDXs), tobacco-exposed mice and genetically engineered mouse models. A neutralising monoclonal antibody against IL-11RA was produced and tested., [Results] Our findings revealed a pivotal role for IL-11 in driving tumourigenesis across various mouse models, highlighting its capacity to modulate tumour immunity towards an immunosuppressive microenvironment. Moreover, we observed a correlation between IL-11 expression and poorer patient outcomes in LUAD. Notably, therapeutic targeting of IL-11RA with a neutralising antibody demonstrated significant anti-tumour efficacy in a PDX model., [Conclusion] The IL-11/IL-11RA axis emerges as a critical driver of LUAD tumourigenesis, exerting its effects through enhanced tumour cell proliferation and remodelling of the tumour microenvironment. Our study highlights the therapeutic potential of disrupting this axis, suggesting that patients exhibiting elevated IL-11 levels may benefit from therapies targeting the IL-11/IL-11RA pathway., We would like to acknowledge patients and their families for donating tumour tissue. We would also like to thank Alicia Maroto Pérez and Carolina Castilla, as well as the Biobank of the Hospital 12 de Octubre and Hospital Virgen del Rocío for kindly providing the samples used in this study. Appreciation is also expressed to Ines Muñoz and Jorge L. Martinez-Torrecuadrada (CNIO) for producing the recombinant human IL-11 and IL-11RA. L.P.-A. was funded by CAM, (B2017/BMD3884, P2022/BMD-7437), Fundación CRIS contra el cancer, CIBERONC (CD16/12/00442) and ISCIII (PI17/00778; PI20/00870; AC20/0070) and I.F. by AECC (AIO2015) and ISCIII (PI16/01311; PI19/00320; CP21/00052) and co-funded by FEDER (European Union). L.O. is funded by the Spanish Ministry of Education (FPU13/02595) and C.C. by ISCIII (CD21/00165). AC was funded by grants from the Ministerio de Ciencia, Innovación y Universidades (MCIU), Plan Estatal de I+D+I 2021, Agencia Estatal de Investigación (AEI), Fondo Europeo de Desarrollo Regional (MCIU/AEI/FEDER, UE): ID2021-122629OB-I00 and CIBER de Cáncer (CB16/12/00275). EASC was funded by U01CA199216 from the National Cancer Institute. S.M.-P. was funded by the Ministry of Health and Social Welfare of the Junta de Andalucía (Nicolas Monardes Program RC-0004-2020, and PECART-0091-2020), Andalusian Research, Development and Innovation Plan (PY20_00992) and ISCIII (PI20/01109) and co-funded by FEDER from Regional Development European Funds (European Union)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Remote activation of enzyme nanohybrids for cancer prodrug therapy controlled by magnetic heating

  • Torres-Herrero, B.
  • Armenia, I.
  • Alleva, M.
  • Asín, L.
  • Correa, S.
  • Ortiz, C.
  • Fernández-Afonso, Y.
  • Gutiérrez, L.
  • Martínez De la Fuente, J.
  • Betancor, L.
  • Grazú, V.
Herein, we have developed nanohybrids (nHs) to remotely activate a therapeutic enzyme for its use in Directed Enzyme Prodrug Therapy (DEPT). The coencapsulation of magnetic nanoparticles (MNPs) with horseradish peroxidase (HRP) using biomimetic silica as an entrapment matrix was optimized to obtain nanosized hybrids (∼150 nm) for remote activation of the therapeutic enzyme. HRP converts indole-3-acetic acid (3IAA) into peroxylated radicals, whereas MNPs respond to alternating magnetic fields (AMFs) becoming local hotspots. The AMF application triggered an increase in the bioconversion rate of HRP matching the activity displayed at the optimal temperature of the nHs (Topt = 50 °C) without altering the temperature of the reaction media. This showed that enzyme nanoactuation is possible with MNPs even if they are not covalently bound. After an extensive physicochemical/magnetic characterization, the spatial location of each component of the nH was deciphered, and an insulating role of the silica matrix was suggested as critical for introducing remote control over HRP. In vitro assays, using a human pancreatic cancer cell line (MIA PaCa-2), showed that only upon exposure to AMF and in the presence of the prodrug, the enzyme-loaded nHs triggered cell death. Moreover, in vivo experiments showed higher reductions in the tumor volume growth in those animals treated with nHs in the presence of 3IAA when exposed to AMF. Thus, this work demonstrates the feasibility of developing a spatiotemporally controlled DEPT strategy to overcome unwanted off-target effects.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Opportunities for nanomaterials in enzyme therapy

  • Torres-Herrero, Beatriz
  • Armenia, Ilaria
  • Ortiz, Cecilia
  • Martínez de la Fuente, Jesús
  • Betancor, Lorena
  • Grazú, Valeria
In recent years, enzyme therapy strategies have rapidly evolved to catalyze essential biochemical reactions with therapeutic potential. These approaches hold particular promise in addressing rare genetic disorders, cancer treatment, neurodegenerative conditions, wound healing, inflammation management, and infectious disease control, among others. There are several primary reasons for the utilization of enzymes as therapeutics: their substrate specificity, their biological compatibility, and their ability to generate a high number of product molecules per enzyme unit. These features have encouraged their application in enzyme replacement therapy where the enzyme serves as the therapeutic agent to rectify abnormal metabolic and physiological processes, enzyme prodrug therapy where the enzyme initiates a clinical effect by activating prodrugs, and enzyme dynamic or starving therapy where the enzyme acts upon host substrate molecules. Currently, there are >20 commercialized products based on therapeutic enzymes, but approval rates are considerably lower than other biologicals. This has stimulated nanobiotechnology in the last years to develop nanoparticle-based solutions that integrate therapeutic enzymes. This approach aims to enhance stability, prevent rapid clearance, reduce immunogenicity, and even enable spatio-temporal activation of the therapeutic catalyst. This comprehensive review delves into emerging trends in the application of therapeutic enzymes, with a particular emphasis on the synergistic opportunities presented by incorporating enzymes into nanomaterials. Such integration holds the promise of enhancing existing therapies or even paving the way for innovative nanotherapeutic approaches.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Cr3+-Doped γ- and β-Gallium Oxide Nanoprobes for Bioimaging: Synthesis, Persistent Luminescence, and Biocompatibility

  • Arroyo, Encarnación
  • Monje-Moreno, José M.
  • Torres-Herrero, Beatriz
  • Munoz, Manuel J.
  • Martínez de la Fuente, Jesús
  • Becerro, Ana I.
  • Ocaña, Manuel
Persistent luminescent (PersL) nanophosphors that emit in the near infrared (NIR) region are promising nanoprobes for in vivo bioimaging. Although Cr3+‐doped zinc gallate nanoparticles (NPs) have been widely studied as in vivo bioimaging nanoprobes due to their NIR PersL emission at 695 nm, the simpler Cr3+‐doped gallium oxide system has been less explored despite its deeper NIR emission (760 nm), which favors tissue penetration. This is likely due the lack of synthesis methods that render Ga2O3‐based NPs suitable for in vivo applications. In this paper, a novel method for the synthesis of uniform and hydrophilic γ‐Ga2O3:Cr3+ NPs is reported, whose photoluminescence (PL) and PersL are optimized by adjusting their Cr3+ content. Such properties are further greatly improved through an annealing process at high temperature, which result in the transformation of its crystal structure into the β‐phase. The obtained β‐Ga2O3:Cr3+ NPs are colloidally stable in a physiological pH simulator medium and are nontoxic for cells. Finally, this work studies, for the first time in literature, the in vivo biocompatibility of such NPs using a Caenorhabditis elegans (C. elegans) animal model, finding that their morbidity and reproductive toxicity are negligible. In summary, the reported NPs are excellent candidates for their use as a NIR PersL probes for in vivo bioimaging.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease

  • Verheijen, Jan
  • Van den Bossche, Tobi
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Graff, Caroline|||0000-0002-9949-2951
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Pastor, Pau|||0000-0002-7493-8777
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Martins, Madalena|||0000-0001-8360-6806
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Bettens, Karolien
  • Mateiu, Ligia
  • Dillen, Lubina
  • Cras, Patrick|||0000-0002-7265-7429
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
The sortilin-related receptor 1 (SORL1) gene has been associated with increased risk for Alzheimer's disease (AD). Rare genetic variants in the SORL1 gene have also been implicated in autosomal dominant early-onset AD (EOAD). Here we report a large-scale investigation of the contribution of genetic variability in SORL1 to EOAD in a European EOAD cohort. We performed massive parallel amplicon-based re-sequencing of the full coding region of SORL1 in 1255 EOAD patients and 1938 age- and origin-matched control individuals in the context of the European Early-Onset Dementia (EOD) consortium, originating from Belgium, Spain, Portugal, Italy, Sweden, Germany, and Czech Republic. We identified six frameshift variants and two nonsense variants that were exclusively present in patients. These mutations are predicted to result in haploinsufficiency through nonsense-mediated mRNA decay, which could be confirmed experimentally for SORL1 p.Gly447Argfs*22 observed in a Belgian EOAD patient. We observed a 1.5-fold enrichment of rare non-synonymous variants in patients (carrier frequency 8.8 %; SkatOMeta p value 0.0001). Of the 84 non-synonymous rare variants detected in the full patient/control cohort, 36 were only detected in patients. Our findings underscore a role of rare SORL1 variants in EOAD, but also show a non-negligible frequency of these variants in healthy individuals, necessitating the need for pathogenicity assays. Premature stop codons due to frameshift and nonsense variants, have so far exclusively been found in patients, and their predicted mode of action corresponds with evidence from in vitro functional studies of SORL1 in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease

  • De Roeck, Arne
  • Van den Bossche, Tobi
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Verheijen, Jan
  • De Coster, Wouter
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • Dillen, Lubina
  • Baradaran-Heravi, Yalda
  • Heeman, Bavo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Gómez-Tortosa, Estrella
  • Pastor, Pau|||0000-0002-7493-8777
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Graff, Caroline|||0000-0002-9949-2951
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Martins, Madalena|||0000-0001-8360-6806
  • Borroni, Barbara|||0000-0001-9340-9814
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Santana, Isabel|||0000-0002-8114-9434
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Koutroumani, Maria
  • Matej, Radoslav|||0000-0002-6152-6343
  • Rohan, Zdenek|||0000-0003-3501-6179
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Cras, Patrick|||0000-0002-7265-7429
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
Premature termination codon (PTC) mutations in the ATP-Binding Cassette, Sub-Family A, Member 7 gene (ABCA7) have recently been identified as intermediate-to-high penetrant risk factor for late-onset Alzheimer's disease (LOAD). High variability, however, is observed in downstream ABCA7 mRNA and protein expression, disease penetrance, and onset age, indicative of unknown modifying factors. Here, we investigated the prevalence and disease penetrance of ABCA7 PTC mutations in a large early onset AD (EOAD)-control cohort, and examined the effect on transcript level with comprehensive third-generation long-read sequencing. We characterized the ABCA7 coding sequence with next-generation sequencing in 928 EOAD patients and 980 matched control individuals. With MetaSKAT rare variant association analysis, we observed a fivefold enrichment (p = 0.0004) of PTC mutations in EOAD patients (3%) versus controls (0.6%). Ten novel PTC mutations were only observed in patients, and PTC mutation carriers in general had an increased familial AD load. In addition, we observed nominal risk reducing trends for three common coding variants. Seven PTC mutations were further analyzed using targeted long-read cDNA sequencing on an Oxford Nanopore MinION platform. PTC-containing transcripts for each investigated PTC mutation were observed at varying proportion (5-41% of the total read count), implying incomplete nonsense-mediated mRNA decay (NMD). Furthermore, we distinguished and phased several previously unknown alternative splicing events (up to 30% of transcripts). In conjunction with PTC mutations, several of these novel ABCA7 isoforms have the potential to rescue deleterious PTC effects. In conclusion, ABCA7 PTC mutations play a substantial role in EOAD, warranting genetic screening of ABCA7 in genetically unexplained patients. Long-read cDNA sequencing revealed both varying degrees of NMD and transcript-modifying events, which may influence ABCA7 dosage, disease severity, and may create opportunities for therapeutic interventions in AD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genetic variability in SQSTM1 and risk of early-onset Alzheimer dementia, A European early-onset dementia consortium study

  • Cuyvers, Elise
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Bettens, Karolien
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Vandenbulcke, Mathieu
  • Robberecht, Caroline
  • Dillen, Lubina
  • Merlin, Céline
  • Geerts, Nathalie
  • Graff, Caroline|||0000-0002-9949-2951
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Chiang, Huei-Hsin
  • Pastor, Pau|||0000-0002-7493-8777
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Santana, Isabel|||0000-0002-8114-9434
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Martins, Madalena|||0000-0001-8360-6806
  • Borroni, Barbara|||0000-0001-9340-9814
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Matej, Radoslav|||0000-0002-6152-6343
  • Rohan, Zdenek|||0000-0003-3501-6179
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Fabrizi, Gian Maria|||0000-0001-6804-0226
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
Meta-analysis of existing genome-wide association studies on Alzheimer's disease (AD) showed subgenome-wide association of an intronic variant in the sequestosome 1 (SQSTM1) gene with AD. We performed targeted resequencing of SQSTM1 in Flanders-Belgian AD patients selected to be enriched for a genetic background (n = 435) and geographically matched nonaffected individuals (n = 872) to investigate the role of both common and rare SQSTM1 variants. Results were extended to the European early-onset dementia cohorts (926 early-onset Alzheimer's disease [EOAD] patients and 1476 nonaffected individuals). Of the 61 detected exonic variants in SQSTM1, the majority were rare (n = 57). Rare variant (minor allele frequency <0.01) burden analysis did not reveal an increased frequency of rare variants in EOAD patients in any of the separate study populations nor when meta-analyzing all cohorts. Common variants p.D292= and p.R312= showed nominal association with AD (odds ratio= 1.11 [95% confidence interval= 1-1.22], p= 0.04), only when including the Flanders-Belgian cohort in the meta-analysis. We cannot exclude a role of SQSTM1 genetic variability in late-onset AD, but our data indicate that SQSTM1 does not play a major role in the etiology of EOAD.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rare mutations in SQSTM1 modify susceptibility to frontotemporal lobar degeneration

  • Van der Zee, Julie|||0000-0003-4381-8040
  • Van Langenhove, Tim
  • Kovacs, Gabor G.|||0000-0003-3841-5511
  • Dillen, Lubina
  • Deschamps, William
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Matej, Radoslav|||0000-0002-6152-6343
  • Vandenbulcke, Mathieu
  • Sieben, Anne|||0000-0003-1278-6605
  • Dermaut, Bart
  • Smets, Katrien
  • Van Damme, Philip|||0000-0002-4010-2357
  • Merlin, Celine
  • Laureys, Annelies
  • Van Den Broeck, Marleen
  • Mattheijssens, Maria
  • Peeters, Karin
  • Benussi, Luisa|||0000-0003-2836-8141
  • Binetti, Giuliano|||0000-0003-2759-5844
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Borroni, Barbara|||0000-0001-9340-9814
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Archetti, Silvana
  • Pastor, Pau|||0000-0002-7493-8777
  • Razquín, Cristina|||0000-0003-3480-2645
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Hernández, Isabel|||0000-0001-8119-393X
  • Boada, Mercè|||0000-0003-2617-3009
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Miltenberger-Miltényi, Gabriel|||0000-0003-0224-1281
  • Simões do Couto, Frederico|||0000-0002-3916-2598
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Bagnoli, Silvia
  • Graff, Caroline|||0000-0002-9949-2951
  • Chiang, Huei-Hsin
  • Thonberg, Hakan
  • Perneczky, Robert|||0000-0003-1981-7435
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Bonvicini, Cristian|||0000-0003-1577-2823
  • Synofzik, Matthis|||0000-0002-2280-7273
  • Maetzler, Walter|||0000-0002-5945-4694
  • Vom Hagen, Jennifer Müller
  • Schöls, Ludger|||0000-0001-7774-5025
  • Haack, Tobias B.|||0000-0001-6033-4836
  • Strom, Tim M.
  • Prokisch, Holger|||0000-0003-2379-6286
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Santana, Isabel|||0000-0002-8114-9434
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Santiago, Beatriz
  • Heneka, Michael|||0000-0003-4996-1630
  • Jessen, Frank
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Sarafov, Stayko
  • Tournev, Ivailo
  • Jordanova, Albena
  • Parobkova, Eva
  • Fabrizi, Gian Maria|||0000-0001-6804-0226
  • Testi, Silvia|||0000-0003-0267-0000
  • Salmon, Eric|||0000-0003-2520-9241
  • Ströbel, Thomas
  • Santens, Patrick|||0000-0002-8886-9776
  • Robberecht, Wim
  • De Jonghe, Peter
  • Martin, Jean-Jacques
  • Cras, Patrick|||0000-0002-7265-7429
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Cruts, Marc|||0000-0002-1338-992X
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
Mutations in the gene coding for Sequestosome 1 (SQSTM1) have been genetically associated with amyotrophic lateral sclerosis (ALS) and Paget disease of bone. In the present study, we analyzed the SQSTM1 coding sequence for mutations in an extended cohort of 1,808 patients with frontotemporal lobar degeneration (FTLD), ascertained within the European Early-Onset Dementia consortium. As control dataset, we sequenced 1,625 European control individuals and analyzed whole-exome sequence data of 2,274 German individuals (total n = 3,899). Association of rare SQSTM1 mutations was calculated in a meta-analysis of 4,332 FTLD and 10,240 control alleles. We identified 25 coding variants in FTLD patients of which 10 have not been described. Fifteen mutations were absent in the control individuals (carrier frequency <0.00026) whilst the others were rare in both patients and control individuals. When pooling all variants with a minor allele frequency <0.01, an overall frequency of 3.2 % was calculated in patients. Rare variant association analysis between patients and controls showed no difference over the whole protein, but suggested that rare mutations clustering in the UBA domain of SQSTM1 may influence disease susceptibility by doubling the risk for FTLD (RR = 2.18 [95 % CI 1.24-3.85]; corrected p value = 0.042). Detailed histopathology demonstrated that mutations in SQSTM1 associate with widespread neuronal and glial phospho-TDP-43 pathology. With this study, we provide further evidence for a putative role of rare mutations in SQSTM1 in the genetic etiology of FTLD and showed that, comparable to other FTLD/ALS genes, SQSTM1 mutations are associated with TDP-43 pathology. © 2014 The Author(s).